AUTL — Autolus Therapeutics Share News
0.000.00%
Last trade - 00:00- $428.49m
- $476.32m
- $75.39m
Autolus Therapeutics tumbles on deep-discounted $150 mln share offering
Brief: Autolus Announces Pricing Of Public Offering
Autolus Therapeutics tumbles after launching share offering
Brief: Autolus Therapeutics To Receive $70 Million In Milestone Payments From Blackstone Life Sciences
Brief: Autolus Announces Proposed Public Offering In The United States
Brief: Autolus Therapeutics Announces Pivotal Phase 2 Felix Clinical Trial Has Met Primary Endpoint At Interim Analysis
Brief: Autolus Therapeutics Handovers Clean Rooms Forming Basis Of New Commercial Manufacturing Facility In UK
Autolus Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Brief: Autolus Therapeutics Reports Third Quarter 2022 Financial Results
Autolus Therapeutics PLC expected to post a loss of 46 cents a share - Earnings Preview
Autolus up as Moderna exercises option for licensing targeting technology
Brief: Moderna Exercises Option To License Proprietary Targeting Technology From Autolus
Autolus soars on deal granting Bristol Myers access to 'safety switch' tech
Brief: Autolus Therapeutics Announces Collaboration With Bristol Myers Squibb For Use Of Autolus’ Proprietary Safety Switch System
Brief: Gain Therapeutics Promotes Matthias Alder To Chief Executive Officer
Brief: Autolus Therapeutics Reports Q2 2022 Financial Results
Brief: Autolus Therapeutics Presents Clinical Data Updates At European Hematology Association Congress
Autolus Therapeutics PLC reports results for the quarter ended in March - Earnings Summary
Brief: Autolus Therapeutics Reports First Quarter 2022 Financial Results